National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

An Economic Evaluation of Eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
20/01/2010 March 2010 Reimbursement not Recommended

Alexion Pharma UK. Ltd have failed to demonstrate the cost-effectiveness of eculizumab  (Soliris®) for the treatment of PNH in the Irish healthcare setting.

Eculizumab (Soliris®) Summary 2010 

Pharmacoeconomic Reassessment

Commenced Completed Outcome
15/07/2013  14/10/2013 Reimbursement not Recommended

The NCPE do not believe that eculizumab (Soliris®) is value for money for the treatment of patients with PNH in the Irish Healthcare setting

Eculizumab (Soliris) Summary 2013